Clinical Trial

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Study acronym: Portal
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-10-31 -> 2029-12-31 2026-06-05
minor Completion pushed: 2029-10-31 -> 2029-12-31 2026-06-05
Trial Details
NCT Number NCT03683251
Lead Sponsor Hoffmann-La Roche
Conditions Neovascular Age-Related Macular Degeneration
Enrollment 1,000 participants
Start Date 2018-09-20
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06